Pentosidine and Increased Fracture Risk in Older Adults with Type 2 Diabetes
2009/04/21 by Ann V. Schwartz, Patrick Garnero, Teresa A. Hillier +10 · 26 citations
Biochemistry, Genetics and Molecular Biology · Dentistry · #Advanced Glycation End Products research #Bone Metabolism and Diseases #Oral microbiology and periodontitis research
paper · doi:10.1210/jc.2008-2498
Abstract
CONTEXT: Type 2 diabetes is associated with higher fracture risk at a given bone mineral density. Advanced glycation endproducts (AGEs) accumulate in bone collagen with age and diabetes and may weaken bone. OBJECTIVE: The aim was to determine whether urine pentosidine, an AGE, was associated with fractures in older adults with and without diabetes. DESIGN: We performed an observational cohort study. SETTING: We used data from the Health, Aging and Body Composition prospective study of white and black, well-functioning men and women ages 70-79 yr. PARTICIPANTS: Participants with (n = 501) and without (n = 427) diabetes were matched on gender, race, and study site. PREDICTOR: Urine pentosidine was assayed from frozen stored baseline specimens. MAIN OUTCOME MEASURES: Incident clinical fractures and baseline vertebral fractures were measured. RESULTS: Despite higher bone mineral density, clinical fracture incidence (14.8 vs. 12.6%) and vertebral fracture prevalence (2.3 vs. 2.9%) were not lower in those with diabetes (P > 0.05). In multivariable models, pentosidine was associated with increased clinical fracture incidence in those with diabetes [relative hazard, 1.42; 95% confidence interval (CI), 1.10, 1.83, for 1 sd increase in log pentosidine] but not in those without diabetes (relative hazard, 1.08; 95% CI, 0.79, 1.49; P value for interaction = 0.030). In those with diabetes, pentosidine was associated with increased vertebral fracture prevalence (adjusted odds ratio, 5.93; 95% CI, 2.08, 16.94, for 1 sd increase in log pentosidine) but not in those without diabetes (adjusted odds ratio, 0.74; 95% CI, 0.30, 1.83; P value for interaction = 0.005). CONCLUSIONS: Higher pentosidine levels are a risk factor for fracture in older adults with diabetes and may account in part for reduced bone strength in type 2 diabetes.
Cited by
- Advanced Glycation End Product 3 (AGE3) Increases Apoptosis and the Expression of Sclerostin by Stimulating TGF-β Expression and Secretion in Osteocyte-Like MLO-Y4-A2 Cells
- Diabetes and fractures: an overshadowed association. [europepmc]
- Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. [europepmc]
- Bone structure and turnover in type 2 diabetes mellitus. [europepmc]
- Type 2 diabetes and bone fractures. [europepmc]
- Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. [europepmc]
- Nanoscale changes in collagen are reflected in physical and mechanical properties of bone at the microscale in diabetic rats. [europepmc]
- A review of rodent models of type 2 diabetic skeletal fragility. [europepmc]
- Fracture risk in diabetic elderly men: the MrOS study. [europepmc]
- Childhood obesity, bone development, and cardiometabolic risk factors. [europepmc]
- Determinants of bone strength and quality in diabetes mellitus in humans. [europepmc]
- Nonenzymatic Glycation and Degree of Mineralization Are Higher in Bone From Fractured Patients With Type 1 Diabetes Mellitus. [europepmc]
- Advanced Glycation End-products and Bone Fractures. [europepmc]
- Advanced Glycation End Products, Diabetes, and Bone Strength. [europepmc]
- Diabetes, bone and glucose-lowering agents: basic biology. [europepmc]
- Accumulation of carboxymethyl-lysine (CML) in human cortical bone. [europepmc]
- Diabetes mellitus and bone health: epidemiology, etiology and implications for fracture risk stratification. [europepmc]
- Bone microarchitecture, biomechanical properties, and advanced glycation end-products in the proximal femur of adults with type 2 diabetes. [europepmc]
- Diagnosis and management of bone fragility in diabetes: an emerging challenge. [europepmc]
- Update on the impact of type 2 diabetes mellitus on bone metabolism and material properties. [europepmc]
- Advanced Glycation End Products (AGEs), Receptor for AGEs, Diabetes, and Bone: Review of the Literature. [europepmc]
- Impact of Diabetes Mellitus on Bone Health. [europepmc]
- Accelerated osteocyte senescence and skeletal fragility in mice with type 2 diabetes. [europepmc]
- Pathophysiology and Management of Type 2 Diabetes Mellitus Bone Fragility. [europepmc]
- Update on the pathogenesis and treatment of skeletal fragility in type 2 diabetes mellitus. [europepmc]
- Advanced glycation and glycoxidation end products in bone. [europepmc]
Related